一个用于研究对自然杀伤细胞敏感性的患者来源的卵巢癌类器官平台。
A patient-derived ovarian cancer organoid platform to study susceptibility to natural killer cells.
作者信息
Mercadante Marisa, Scheben Armin, Estrada Jacob, Savas-Carstens Jan, Sullivan William, Housel Nicholas, Volpari Tatiana, Hebner Jax, Sapar Maria, Rusielewicz Tom, Monsma Frederick J, Semrau Stefan, Wang Yinan, Martin Laura A
机构信息
The New York Stem Cell Foundation Research Institute, New York, NY.
The Stevens Institute of Technology, Hoboken, NJ.
出版信息
bioRxiv. 2025 Mar 7:2025.03.06.641285. doi: 10.1101/2025.03.06.641285.
Intratumoral heterogeneity drives therapy resistance and relapses in advanced stage cancers, such as ovarian cancer. Here, we present a live cell imaging assay using patient-derived ovarian cancer organoids for real time capture and quantification of natural killer cell-mediated apoptotic events in >500 organoids simultaneously. Our assay revealed significant inter- and intratumor response heterogeneity and identified a rare resistant organoid population, opening avenues to test immunomodulatory strategies that overcome resistance.
肿瘤内异质性导致晚期癌症（如卵巢癌）产生治疗抗性和复发。在此，我们展示了一种活细胞成像分析方法，该方法使用患者来源的卵巢癌类器官，可同时实时捕获和量化500多个类器官中自然杀伤细胞介导的凋亡事件。我们的分析揭示了显著的肿瘤间和肿瘤内反应异质性，并鉴定出一种罕见的抗性类器官群体，为测试克服抗性的免疫调节策略开辟了道路。
Zotero 插件